Enhanced microglial activation has been documented in Magnetic Resonance Imaging (MRI)–detected inflammatory lesions in MS patients with active disease, while the association between the level of TSPO binding, clinical disability, and the effect of MS therapeutics on microglial activation are still discussed [98]. Here, TSPO is linked to myeloid sarcoma.